Combat Against Gynecological Cancers with Blood Vessels As Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2023 Jun 14

PMID 37312935

Authors

Shan Yang

Weidong Fei

Yunchun Zhao

Fengmei Wang

Yiqing Ye

Fenfen Wang

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is an essential mechanism for the progression of gynecological cancers. Although approved anti-angiogenic drugs have demonstrated clinical efficacy in treating gynecological cancers, the full potential of therapeutic strategies based on tumor blood vessels has not yet been realized. This review summarizes the latest angiogenesis mechanisms involved in the progression of gynecological cancers and discusses the current clinical practice of approved anti-angiogenic drugs and related clinical trials. Given the close relationship between gynecological cancers and blood vessels, we highlight more delicate strategies for regulating tumor vessels, including wise drug combinations and smart nano-delivery platforms to achieve highly efficient drug delivery and overall vessel microenvironment regulation. We also address current challenges and future opportunities in this field. We aim to generate interest in therapeutic strategies that target blood vessels as a key entry point and offer new potential and inspiration for combating gynecological cancers.

Citing Articles

Advances in lysosomal escape mechanisms for gynecological cancer nano-therapeutics.

Wei H, Hao Y, Zhang J, Qi Y, Feng C, Zhang C J Pharm Anal. 2025; 14(12):101119.

PMID: 39811489 PMC: 11732538. DOI: 10.1016/j.jpha.2024.101119.

Recent development of nanotechnology-based approaches for gynecologic cancer therapy.

Gedda G, Park Y, Pang M Obstet Gynecol Sci. 2024; 68(1):18-29.

PMID: 39591955 PMC: 11788694. DOI: 10.5468/ogs.24180.

Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.

Anderson T, McCormick A, Daugherity E, Oladejo M, Okpalanwaka I, Smith S Oncoimmunology. 2023; 12(1):2260620.

PMID: 37781234 PMC: 10540654. DOI: 10.1080/2162402X.2023.2260620.

References

Bender D, Sill M, Lankes H, Reyes H, Darus C, Delmore J . A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015; 138(3):507-12. PMC: 4642817. DOI: 10.1016/j.ygyno.2015.07.018. View

Campos S, Penson R, Matulonis U, Horowitz N, Whalen C, Pereira L . A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2012; 128(2):215-20. DOI: 10.1016/j.ygyno.2012.07.126. View

Yan Y, Chen B, Wang Z, Yin Q, Wang Y, Wan F . Sequential Modulations of Tumor Vasculature and Stromal Barriers Augment the Active Targeting Efficacy of Antibody-Modified Nanophotosensitizer in Desmoplastic Ovarian Carcinoma. Adv Sci (Weinh). 2021; 8(3):2002253. PMC: 7856881. DOI: 10.1002/advs.202002253. View

Powell M, Sill M, Goodfellow P, Benbrook D, Lankes H, Leslie K . A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014; 135(1):38-43. PMC: 4278402. DOI: 10.1016/j.ygyno.2014.07.083. View

Gharpure K, Chu K, Bowerman C, Miyake T, Pradeep S, Mangala S . Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014; 13(7):1750-7. PMC: 4090269. DOI: 10.1158/1535-7163.MCT-13-0930. View

Chen S, Li T, Meng L, Liu K . Advances in immunotherapy and molecular targeted therapy of gestational trophoblastic tumor: current practice and future perspectives. Am J Cancer Res. 2022; 12(6):2422-2432. PMC: 9251702. View

Seyyednia E, Oroojalian F, Baradaran B, Shahbazi Mojarrad J, Mokhtarzadeh A, Valizadeh H . Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging. J Control Release. 2021; 338:367-393. DOI: 10.1016/j.jconrel.2021.08.044. View

Matei D, Sill M, Lankes H, DeGeest K, Bristow R, Mutch D . Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2010; 29(1):69-75. PMC: 3055861. DOI: 10.1200/JCO.2009.26.7856. View

Fu S, Corr B, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R . Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022; 40(23):2568-2577. PMC: 9362870. DOI: 10.1200/JCO.21.01801. View

10.

Ebeid K, Meng X, Thiel K, Do A, Geary S, Morris A . Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 2017; 13(1):72-81. PMC: 5762267. DOI: 10.1038/s41565-017-0009-7. View

11.

Morgan R, Banerjee S, Hall M, Clamp A, Zhou C, Hasan J . Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecol Oncol. 2020; 156(3):545-551. DOI: 10.1016/j.ygyno.2020.01.005. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Zhang L, Chen L, Yu H . Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients. Invest New Drugs. 2019; 38(4):1186-1191. DOI: 10.1007/s10637-019-00858-5. View

14.

Winer I, Wang S, Lee Y, Lee Y, Fan W, Gong Y . F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010; 70(21):8674-83. PMC: 2970692. DOI: 10.1158/0008-5472.CAN-10-1917. View

15.

Jin C, Yuan M, Bu H, Jin C . Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. J Oncol. 2022; 2022:4880355. PMC: 9019437. DOI: 10.1155/2022/4880355. View

16.

Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A . Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study. Gynecol Oncol. 2022; 166(3):389-396. DOI: 10.1016/j.ygyno.2022.06.022. View

17.

Boeldt D, Bird I . Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. J Endocrinol. 2016; 232(1):R27-R44. PMC: 5115955. DOI: 10.1530/JOE-16-0340. View

18.

Zhang M, Tian Z, Sun Y . Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report. Medicine (Baltimore). 2017; 96(45):e8570. PMC: 5690771. DOI: 10.1097/MD.0000000000008570. View

19.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

20.

Troendle E, Khan A, Searson P, Ulmschneider M . Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks. J Control Release. 2018; 292:221-234. PMC: 10131895. DOI: 10.1016/j.jconrel.2018.11.010. View